Varex Imaging (VREX) Q2 2026 Earnings Transcript

Varex Imaging reported Q2 revenue of $216 million, up 1% year over year, with non-GAAP EPS of $0.21 in line with expectations and non-GAAP gross margin of 34% at the high end of guidance. Management reinstated full-year guidance for revenue of $860 million-$880 million and non-GAAP EPS of $0.80-$1.00, while also highlighting a debt refinancing that cut leverage to 2.2x adjusted EBITDA. Offsetting the solid quarter were lower margins from higher costs, a $1.8 million Micro-X mark-to-market charge, and elevated inventory tied to India ramp-up and cargo inspection implementations.

Analysis

The key inflection is not the quarter itself, but the shape of the earnings bridge: management is explicitly moving from a cost-absorption phase into a utilization/operating-leverage phase. That matters because the current margin drag is largely self-inflicted by India ramp, cargo-system implementation, and inventory positioning; once throughput normalizes, the P&L can improve faster than the modest top-line growth would suggest. The market is likely underestimating how much incremental EBITDA can flow through if detector utilization in India gets to the 60%-70% range by year-end, since that should reverse both gross margin dilution and some of the current OpEx inefficiency.

The second-order bullish effect is on cash conversion, not just earnings. Inventory is elevated for reasons that should unwind over the next two quarters, and the company now has a lower interest burden after refinancing, so any reduction in working capital should have an outsized effect on equity value through both FCF and leverage optics. If inventory normalizes while revenue holds near the guided range, leverage could step down quickly, which is the cleanest catalyst for multiple expansion in a name like this.

The contrarian read is that the most important growth engine may not be medical CT at all, but industrial security and nondestructive inspection, where the demand is lumpier but the addressable market is broader and less dependent on one OEM launch cycle. Consensus may still be valuing this as a slow industrial-medical parts supplier, while management is telegraphing a transition toward a higher-quality mix with more systems content and software-like stickiness. The main risk is timing: if India approvals slip or cargo deployments take longer to accept, the market could punish the stock for another 1-2 quarters even if the longer-term thesis remains intact.

Key Decisions for Investors

• Initiate a tactical long in VREX over the next 2-4 weeks; target upside into the next 1-2 quarters as India utilization and inventory reduction start to show up. Use a 10%-15% downside stop because the name remains execution-sensitive and liquidity can gap on weak quarters.
• Pair trade: long VREX / short a slower-growth med-tech component peer with less operating leverage. The thesis is that VREX has more near-term catalyst density from working-capital release, refinancing, and margin rebound, while the short leg should be a cleaner multiple comp rather than a macro hedge.
• Buy VREX call spreads expiring 3-6 months out to express the operating-leverage setup without taking full balance-sheet risk. The best payoff is if the stock rerates before the market waits for full India ramp confirmation.
• Add only on post-earnings weakness if the selloff is driven by margin noise rather than demand deterioration. The risk/reward improves materially if the market gives a lower entry on unchanged guidance and stable end-market commentary.
• For more defensive exposure, consider a small long VREX / short industrial capex basket if the market starts to discount a global slowdown; VREX’s demand drivers are more idiosyncratic than cyclically tied, and refinancing should cushion drawdowns.